National Institute of Health Awards Insightful Corporation Grant Worth Nearly $750,000.

Insightful to develop least angle regression software (LARS) to aid in medical diagnosis, detection of cancer, and feature selection in microarrays

SEATTLE -- Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced today that the National Institute of Health (NIH) has awarded Insightful a grant of $749,592 to conduct a two-year Phase II SBIR research and development project on least angle regression (LARS). This project calls for Insightful to develop an easy-to-use and flexible LARS solution that may be used for medical diagnosis, detection of cancer, feature selection in microarrays, and modeling patient characteristics like blood pressure. The NIH has funded this project under grant number 2R44GM074313-02.

"Researchers and academics believe that LARS has great potential, but up till now the academic software available has been limited in scope and refinement," said Dr. Jill R. Goldschneider, director of research at Insightful. "We are excited by this opportunity granted by the NIH to develop robust and easy-to-use LARS software that will enable medical researchers to obtain high prediction accuracy and to obtain stable and interpretable results in high-dimensional situations."

The Phase II research and development project follows an earlier Phase I research and development project for the NIH. Phase I work demonstrated feasibility by extending least angle regression work in three key directions: categorical predictors, logistics regression and a numerically accurate implementation. The outcome of Phase I was an open-source prototype library for generalized least angle regression called GLARS (available for download at http://csan.insightful.com/) for S-PLUS[R] and R, including contributions from outside researchers.

Led by Dr. Tim Hesterberg, senior research scientist at Insightful, the LARS team plans to produce superior methods and software for classification and regression when there are many potential predictor variables to choose from. The goals for Phase II include extensions to other types of explanatory variables (e.g. polynomial or spline functions and interactions between variables), to survival and other additional regression models, and to handle missing data and massive data sets.

"We're excited about working in the open-source environment," said Hesterberg. "Contributions from outside researchers have long been a major advantage of S-PLUS. Open-source work allows us to harness the explosion of academic work and provides an agility that can't be matched by traditional statistics packages."

Funding from the award will be recorded in the company's financial statements as a reduction to research and development expense.

ABOUT INSIGHTFUL

Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions. Insightful products S-PLUS([R]), Insightful Miner([TM]), S-PLUS([R]) Server and InFact([R]) provide companies with the knowledge to act[TM]. Insightful consulting services provide specialized expertise and proven processes for the design, development and deployment of customized solutions. The company has been delivering industry-leading, high-ROI solutions to thousands of companies in financial services, life sciences, biotechnology, telecommunications, and manufacturing, plus government and research institutions, for more than 18 years. Headquartered in Seattle, Insightful has offices in North Carolina, France, Switzerland, and the United Kingdom, with distributors around the world. For more information, visit www.insightful.com, email [e-mail] or call 1-800-569-0123.

Note to Investors - Forward-Looking Statements 

This press release contains forward-looking statements, including statements about expected government funding and about the potential performance, features, and advantages of future software products. Forward-looking statements are based on the judgment and opinions of management at the time the statements are made. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed or implied by the forward-looking statements for a number of reasons, including, without limitation, the risk that we do not receive the government funding that we expect to receive or our new products do not perform as designed and expected. More detailed information regarding these and other factors that could affect actual results is set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-QSB. You should not unduly rely on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of anticipated events.